1. Home
  2. DH vs ESPR Comparison

DH vs ESPR Comparison

Compare DH & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Definitive Healthcare Corp.

DH

Definitive Healthcare Corp.

HOLD

Current Price

$1.08

Market Cap

116.0M

Sector

Technology

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$2.61

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DH
ESPR
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.0M
731.9M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
DH
ESPR
Price
$1.08
$2.61
Analyst Decision
Hold
Strong Buy
Analyst Count
5
5
Target Price
$3.08
$7.60
AVG Volume (30 Days)
328.2K
5.2M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
63.28
60.71
EPS
N/A
N/A
Revenue
$241,521,000.00
$403,135,000.00
Revenue This Year
N/A
$2.92
Revenue Next Year
$0.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.31
52 Week Low
$0.97
$0.73
52 Week High
$4.70
$4.18

Technical Indicators

Market Signals
Indicator
DH
ESPR
Relative Strength Index (RSI) 37.93 43.81
Support Level $1.02 $2.37
Resistance Level $1.25 $3.02
Average True Range (ATR) 0.10 0.19
MACD 0.03 0.03
Stochastic Oscillator 39.78 47.02

Price Performance

Historical Comparison
DH
ESPR

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: